# Rupert Bartsch

Source: https://onco.cc/people/rupert-bartsch/  
OnCo record `rupert-bartsch` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vienna oncologist who led TUXEDO-1, the small trial that showed trastuzumab deruxtecan can shrink active brain metastases from HER2-positive breast cancer.

## Summary

Rupert Bartsch is a medical oncologist at the Medical University of Vienna who focuses on brain metastases from breast cancer. He was first author of the 2022 Nature Medicine report of TUXEDO-1, a single-arm phase 2 trial in which trastuzumab deruxtecan produced intracranial responses in most patients with active brain metastases from HER2-positive breast cancer, evidence that the antibody-drug conjugate works in the brain.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: breast; brain-metastases; trialist
- Role: Medical oncologist, Medical University of Vienna
- Specialisms: Breast cancer brain metastases; HER2-positive breast cancer; Antibody-drug conjugates

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HER2-positive breast cancer with brain metastases](https://onco.cc/cancers/her2-positive-breast-brain-metastases/)
- institutions: [Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH](https://onco.cc/institutions/ccc-vienna/)
- trials: [TUXEDO-1](https://onco.cc/trials/tuxedo-1/)
- key papers: [TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases](https://onco.cc/key-papers/paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022/)

---
JSON: https://onco.cc/api/v1/entities/rupert-bartsch.json